The goal of the Oxford Experimental Cancer Medicine (ECMC) GCP laboratories is to accelerate the development of new cancer treatments by establishing validated assays for cancer biomarkers that can be used to evaluate clinical utility.
Our aim is to describe the distribution and prognostic impact of markers in patient sample collections and evaluate their predictive potential in clinical trials. In order to deliver GCP compliance over the whole translational research process we collaborate with research groups to develop protocols that will produce samples of optimum quality for analysis in validated assays.
Our main areas of biomarker development and validation include tumour marker analysis by automated immnohistochemical staining, and analysis of circulating biomarkers using ELISA. Other studies include western blot analysis of cell signalling proteins and fluorometric detection of drug analytes.
We work with small phase 1/2 clinical trials and larger phase 3 studies and collaborate with groups to either carry out the whole study from development through to analysis of the trial samples, or to provide training on the use of the facilities for translational work.
Liu S et al. Cancer 2015 121:202 Towards operative in vivo fluorescence imaging of c-Met proto-oncogene for personalization of therapy in ovarian cancer
Kevin Myers joined the Oxford ECMC in 2009 as the Senior Scientist to lead the development of GCP quality cancer biomarkers for the Oxford Cancer Centre clinical trials portfolio. He previously worked for Oxford BioMedica developing novel immune cancer therapeutics, building on his post-doctoral research at the Cancer Research UK Manchester Institute.